Table of Contents
Journal of Allergy
Volume 2013, Article ID 130905, 4 pages
http://dx.doi.org/10.1155/2013/130905
Clinical Study

TNF-Alpha Inhibitors for Chronic Urticaria: Experience in 20 Patients

Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, 2400 Copenhagen NV, Denmark

Received 11 June 2013; Accepted 19 August 2013

Academic Editor: Harald Renz

Copyright © 2013 Freja Lærke Sand and Simon Francis Thomsen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Patients with severe chronic urticaria may not respond to antihistamines, and other systemic treatment options may either be ineffective or associated with unacceptable side effects. We present data on efficacy and safety of adalimumab and etanercept in 20 adult patients with chronic urticaria. Twelve (60%) patients obtained complete or almost complete resolution of urticaria after onset of therapy with either adalimumab or etanercept. Further three patients (15%) experienced partial response. Duration of treatment ranged between 2 and 39 months. Those responding completely or almost completely had a durable response with a mean of 11 months. Six patients (30%) experienced side effects and five patients had mild recurrent upper respiratory infections, whereas one patient experienced severe CNS toxicity that could be related to treatment with TNF-alpha inhibitor. Adalimumab and etanercept may be effective and relatively safe treatment options in a significant proportion of patients with chronic urticaria who do not respond sufficiently to high-dose antihistamines or in whom standard immunosuppressive drugs are ineffective or associated with unacceptable side effects.